21 CFR Part 11 Compliance Guide for Small Biotech Startups
Learn 21 CFR Part 11 requirements for electronic records. This guide analyzes cost-effective FDA compliance strategies for small biotechnology startups.
Back to Articles
Articles tagged with “risk-based-approach”
FDA's AI Guidance: 7-Step Credibility Framework Explained
Learn about the FDA's AI guidance for drug development. This article explains the 7-step credibility framework, context of use (COU), and risk-based approach.
A GAMP 5 Guide to AI/ML Validation in GxP Environments
Learn to apply the GAMP 5 risk-based approach for AI/ML validation in GxP environments. This guide covers data integrity, model drift, and regulatory compliance
GAMP 5 Categories Explained: Software, Risk & Examples
Learn the GAMP 5 software categories for computerized system validation. This guide explains each category with examples, risk levels, and how they align with the 2025 ISPE GAMP AI Guide and FDA CSA framework.
Understanding GAMP 5 Guidelines for System Validation
Updated guide to GAMP 5 guidelines for validating computerized systems, covering the 2025 ISPE GAMP AI Guide, FDA CSA final guidance, EU Annex 11/22 drafts, and risk-based lifecycle approach.
GAMP 5: Computerized System Validation in Pharma
This guide explains GAMP 5, its principles, and lifecycle for computerized system validation in pharma, covering regulatory compliance and real-world applications. Updated for 2025-2026 with FDA CSA guidance, EU Annex 11 revision, and ISPE AI Guide.